查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1830989

胃癌市場

Stomach Cancer Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

預計胃癌市場規模將從 2024 年的 51.5 億美元擴大到 2031 年的 119.8 億美元，2025 年至 2031 年的複合年成長率預計為 14.8%。

市場洞察與分析師觀點：胃癌（或稱胃癌）源自於胃內惡性細胞的異常與不受控制的增生。導致胃癌風險的因素包括年齡和飲食習慣。症狀可能包括消化不良、胃痛、食慾不振、胃灼熱和體重減輕。胃癌的治療方案包括化療、放射療法和免疫療法。胃癌市場的成長得益於該疾病發病率的上升、化療、手術和標靶療法等治療方式的進步，以及旨在改善患者預後的持續研發。隨著對早期診斷和個人化治療策略的日益關注，預計胃癌治療市場將在未來幾年繼續保持成長勢頭。

成長催化劑：醫療保健公司正在進行各種研發項目，以開發針對胃癌的創新療法。此外，這些療法正在臨床試驗中進行評估，新的治療方法也不斷發展和探索。一些值得關注的研發產品包括：

2022年12月，浙江多爾生物製品有限公司與默克公司達成臨床試驗合作，旨在評估多爾生物的抗Claudin18.2抗體DR30303與默克的抗PD-1療法KEYTRUDA（帕博利珠單抗）聯合治療胃癌或胃食道結合部癌患者的療效。協議規定，多爾生物將根據雙方商定的方案進行一項實驗研究，以評估DR30303合併KEYTRUDA在Claudin18.2陽性、局部晚期、不可切除或轉移性胃癌或胃食道結合部癌患者中的安全性和有效性。 2022年11月，Triumvira Immunologics發表了其在研TAC-T細胞療法CLDN18.2-TAC T和GUCY2C-TAC T的臨床前研究結果，以及HER2特異性TAC-T產品的資料。該公司公佈了其針對Claudin 18.2的新型T細胞抗原偶聯劑(TAC)-T細胞候選藥物用於治療胃癌的最新資料。 2022年9月，Nuvectis Pharma, Inc.報告了NXP800在ARID1a突變胃癌臨床前異種移植模型的陽性結果。在接受賦形劑或NXP800治療後28天內評估了腫瘤體積，結果顯示與對照組相比，腫瘤消退且生長顯著受到抑制。因此，臨床試驗數量的增加提高了全球胃癌治療的可近性，並對胃癌市場的成長產生了積極影響。

策略洞察報告細分和範圍：胃癌市場按類型、治療、給藥途徑、配銷通路和地理細分。依類型，包括腺癌、胃腸道間質瘤、神經內分泌腫瘤、淋巴瘤等。在治療方面，市場分為標靶和免疫治療藥物、化療和合併藥物等。市場依給藥途徑細分為口服、腸外及其他。分銷管道包括醫院藥房、零售藥房和網路藥房。從地理上講，市場分為北美（美國、加拿大和墨西哥）、歐洲（法國、德國、英國、西班牙、義大利和歐洲其他地區）、亞太地區（中國、印度、日本、澳洲、韓國和亞太其他地區）、中東和非洲（沙烏地阿拉伯、阿拉伯聯合大公國、南非和中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷和南美洲和其他中美洲地區）。

細分分析：胃癌市場依類型分為腺癌、胃腸道間質瘤、神經內分泌腫瘤、淋巴瘤等。腺癌細分市場在2022年佔據了相當大的市場佔有率，預計在2022-2030年期間將呈現最高的複合年成長率。

依治療類型分類，市場分為標靶治療藥物和免疫治療藥物、化療和合併用藥以及其他藥物。 2022年，化療和聯合用藥領域佔據了相當大的市場佔有率，而標靶治療藥物和免疫治療藥物領域預計將在2022年至2030年期間實現最高的複合年成長率。

根據給藥途徑，市場細分為口服、腸外給藥和其他給藥方式。口服給藥在2022年佔據了相當大的市場佔有率，預計在2022-2030年期間將以最快的複合年成長率成長。

就配銷通路而言，市場分為醫院藥房、零售藥房和線上藥房。醫院藥房在2022年佔據了相當大的市場佔有率，預計在2022-2030年期間將實現最高的複合年成長率。

區域分析：胃癌市場主要分為北美、歐洲、亞太地區、南美洲和中美以及中東和非洲。 2022 年，北美佔據了相當大的市場佔有率，其中美國在該地區佔有最大佔有率。北美市場的成長歸因於胃癌發病率的上升、標靶癌症療法的採用率的提高以及癌症研究和治療設施中先進技術的可用性。美國癌症協會預測，2023 年將診斷出約 26,500 例新胃癌病例（男性 15,930 例，女性 10,570 例），預計約有 11,130 人（男性 6,690 例，女性 4,440 例）死於胃癌。北美擁有先進的癌症治療方案，各公司正努力與該地區的老牌企業競爭。

此外，旨在開發針對胃癌患者的有效藥物的臨床試驗數量不斷增加，以及產品上市和獲批數量的增加，預計將推動該地區市場的成長。 2021年4月，美國食品藥物管理局 (FDA) 批准了百時美施貴寶的 Opdivo 合併氟嘧啶和鉑類化療，用於治療晚期或轉移性胃癌和食道腺癌患者。這些進展預計將在預測期內支持該地區的市場成長。

胃癌市場報告範圍產業發展與未來機會：全球胃癌市場主要參與者的幾項措施重點介紹如下：

2021年1月，阿斯特捷利康和第一三共株式會社獲得美國食品藥物管理局（FDA）批准Enhertu用於治療晚期或轉移性HER2陽性胃腺癌成年患者。競爭格局與主要公司：胃癌市場的知名企業包括百時美施貴寶公司、諾華公司、默克公司、禮來公司、Biocon公司、梯瓦製藥工業有限公司、Celltrion Healthcare有限公司、三星Bioepis公司、輝瑞公司和益普生製藥公司。這些公司專注於推出新的高科技產品、增強現有產品線並拓展地理範圍以滿足日益成長的全球需求。

目錄

第1章：簡介

第 2 章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：胃癌市場概況

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表

第5章：胃癌市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：胃癌市場－全球市場分析

  • 胃癌 - 全球市場概覽
  • 胃癌－全球市場及2030年預測

第7章：胃癌​​市場-收入分析-按類型，2020-2030

  • 概述
  • 腺癌
  • 胃腸道間質瘤
  • 神經內分泌腫瘤
  • 淋巴瘤
  • 其他

第 8 章：胃癌市場 - 收入分析 - 依治療方法，2020-2030 年

  • 概述
  • 標靶和免疫治療藥物
  • 化療和合併用藥
  • 其他

第9章：胃癌市場-收入分析-依給藥途徑，2020-2030

  • 概述
  • 口服
  • 腸外
  • 其他

第 10 章：胃癌市場 - 收入分析 - 按配銷通路，2020-2030 年

  • 概述
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 11 章：胃癌市場 - 收入分析，2020-2030 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 12 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 13 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 14 章：胃癌市場 - 關鍵公司簡介

  • Bristol Myers Squibb Company
  • Novartis AG
  • Merck and Co., Inc.
  • Eli Lilly and Company
  • Biocon
  • Teva Pharmaceutical Industries Ltd.
  • Celltrion Healthcare Co., Ltd.
  • Samsung Bioepis
  • Pfizer Inc.
  • Ipsen pharma

第 15 章：附錄

簡介目錄
Product Code: TIPRE00004053

The stomach cancer market is anticipated to expand from US$ 5.15 billion in 2024 to US$ 11.98 billion by 2031, with a projected CAGR of 14.8% from 2025 to 2031.

Market Insights and Analyst Perspective:Stomach cancer, or gastric cancer, arises from the abnormal and uncontrolled proliferation of malignant cells in the stomach. Factors contributing to the risk of stomach cancer include age and dietary habits. Symptoms may include indigestion, stomach pain, loss of appetite, heartburn, and weight loss. Treatment options for stomach cancer include chemotherapy, radiation therapy, and immunotherapy. The growth of the stomach cancer market is driven by the rising incidence of the disease, advancements in treatment modalities such as chemotherapy, surgery, and targeted therapies, as well as ongoing research and development aimed at enhancing patient outcomes. With a growing focus on early diagnosis and personalized treatment strategies, the stomach cancer treatment market is expected to continue its growth trajectory in the coming years.

Growth Catalysts:Healthcare companies are engaging in various research and development initiatives to create innovative treatments for gastric cancer. Furthermore, these treatments are undergoing evaluation in clinical trials, with new methodologies being continuously developed and explored. Some notable products in the pipeline include:

In December 2022, Zhejiang Doer Biologics Co., Ltd entered into a clinical trial collaboration with Merck & Co., Inc. to assess Doer Bio's anti-Claudin18.2 antibody DR30303 in conjunction with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for patients with gastric or gastroesophageal junction cancer. The agreement stipulated that Doer Bio would conduct an experimental study based on a mutually agreed protocol to evaluate the safety and efficacy of DR30303 combined with KEYTRUDA in Claudin18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer patients.In November 2022, Triumvira Immunologics announced preclinical findings for its investigational TAC-T cell therapies CLDN18.2-TAC T and GUCY2C-TAC T, along with data on HER2-specific TAC-T products. The company presented updated data on its novel T cell antigen coupler (TAC)-T cell candidate targeting Claudin 18.2 for gastric cancer treatment.In September 2022, Nuvectis Pharma, Inc. reported positive results for NXP800 in a preclinical xenograft model of ARID1a-mutated gastric carcinoma. Tumor volumes were assessed over 28 days after treatment with either a vehicle or NXP800, showing tumor regression and significant growth inhibition compared to the control.Thus, the increasing number of clinical trials enhances the availability of gastric cancer treatments globally, positively influencing the growth of the stomach cancer market.

Strategic Insights Report Segmentation and Scope:The stomach cancer market is segmented by type, treatment, route of administration, distribution channel, and geography. By type, it includes adenocarcinomas, gastrointestinal stromal tumors, neuroendocrine tumors, lymphoma, and others. In terms of treatment, the market is classified into targeted and immunotherapy drugs, chemotherapy and combination drugs, and others. The market is segmented by route of administration into oral, parenteral, and others. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Geographically, the market is divided into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:The stomach cancer market is categorized by type into adenocarcinomas, gastrointestinal stromal tumors, neuroendocrine tumors, lymphoma, and others. The adenocarcinomas segment held a substantial market share in 2022 and is projected to exhibit the highest CAGR during 2022-2030.

By treatment, the market is divided into targeted and immunotherapy drugs, chemotherapy and combination drugs, and others. In 2022, the chemotherapy and combination drugs segment accounted for a significant market share, while the targeted and immunotherapy drugs segment is expected to show the highest CAGR from 2022 to 2030.

Regarding the route of administration, the market is segmented into oral, parenteral, and others. The oral segment held a notable market share in 2022 and is anticipated to grow at the fastest CAGR during 2022-2030.

In terms of distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held a significant market share in 2022 and is expected to register the highest CAGR during 2022-2030.

Regional Analysis:The stomach cancer market is primarily segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America captured a significant market share, with the US holding the largest share in the region. The growth of the market in North America is attributed to the rising prevalence of gastric cancer, increased adoption of targeted cancer therapies, and the availability of advanced technologies in cancer research and treatment facilities. The American Cancer Society projected approximately 26,500 new cases of gastric cancer (15,930 in males and 10,570 in females) to be diagnosed in 2023, with around 11,130 deaths (6,690 males and 4,440 females) expected due to gastric cancer. North America is well-equipped with advanced treatment options for cancer, and companies are striving to compete with established players in the region.

Additionally, the growing number of clinical trials aimed at developing effective drugs for gastric cancer patients, along with an increase in product launches and approvals, is expected to drive market growth in the region. In April 2021, the Food and Drug Administration (FDA) approved Bristol Myers Squibb's Opdivo, in combination with fluoropyrimidine and platinum-based chemotherapy, for treating patients with advanced or metastatic gastric cancer and esophageal adenocarcinoma. Such developments are likely to support market growth in the region during the forecast period.

Stomach Cancer Market Report Scope Industry Developments and Future Opportunities:Several initiatives by key players in the global stomach cancer market are highlighted below:

In January 2021, AstraZeneca and Daiichi Sankyo Company received FDA approval for Enhertu to treat adult patients with advanced or metastatic HER2-positive gastric adenocarcinoma.

Competitive Landscape and Key Companies:Prominent players in the stomach cancer market include Bristol Myers Squibb Company, Novartis AG, Merck & Co., Inc., Eli Lilly and Company, Biocon, Teva Pharmaceutical Industries Ltd, Celltrion Healthcare Co., Ltd, Samsung Bioepis, Pfizer Inc., and Ipsen Pharma. These companies are focused on launching new high-tech products, enhancing existing offerings, and expanding geographically to meet the increasing global demand.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Stomach Cancer Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Stomach Cancer Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Stomach Cancer Market - Global Market Analysis

  • 6.1 Stomach Cancer - Global Market Overview
  • 6.2 Stomach Cancer - Global Market and Forecast to 2030

7. Stomach Cancer Market - Revenue Analysis (USD Million) - By Type, 2020-2030

  • 7.1 Overview
  • 7.2 Adenocarcinomas
  • 7.3 Gastrointestinal Stromal Tumors
  • 7.4 Neuroendocrine Tumors
  • 7.5 Lymphoma
  • 7.6 Others

8. Stomach Cancer Market - Revenue Analysis (USD Million) - By Treatment, 2020-2030

  • 8.1 Overview
  • 8.2 Targeted and Immunotherapy Drugs
    • 8.2.1 Monoclonal Antibody
    • 8.2.2 Human Epidermal Growth Factor Receptor 2 (HER2)
    • 8.2.3 Checkpoint Inhibitors
  • 8.3 Chemotherapy and Combination Drugs
  • 8.4 Others

9. Stomach Cancer Market - Revenue Analysis (USD Million) - By Route of Administration, 2020-2030

  • 9.1 Overview
  • 9.2 Oral
  • 9.3 Parenteral
  • 9.4 Others

10. Stomach Cancer Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

  • 10.1 Overview
  • 10.2 Hospital Pharmacies
  • 10.3 Retail Pharmacies
  • 10.4 Online Pharmacies

11. Stomach Cancer Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Stomach Cancer Market Overview
    • 11.1.2 North America Stomach Cancer Market Revenue and Forecasts to 2030
    • 11.1.3 North America Stomach Cancer Market Revenue and Forecasts and Analysis - By Type
    • 11.1.4 North America Stomach Cancer Market Revenue and Forecasts and Analysis - By Treatment
    • 11.1.5 North America Stomach Cancer Market Revenue and Forecasts and Analysis - By Route of Administration
    • 11.1.6 North America Stomach Cancer Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 11.1.7 North America Stomach Cancer Market Revenue and Forecasts and Analysis - By Countries
      • 11.1.7.1 United States Stomach Cancer Market
        • 11.1.7.1.1 United States Stomach Cancer Market, by Type
        • 11.1.7.1.2 United States Stomach Cancer Market, by Treatment
        • 11.1.7.1.3 United States Stomach Cancer Market, by Route of Administration
        • 11.1.7.1.4 United States Stomach Cancer Market, by Distribution Channel
      • 11.1.7.2 Canada Stomach Cancer Market
        • 11.1.7.2.1 Canada Stomach Cancer Market, by Type
        • 11.1.7.2.2 Canada Stomach Cancer Market, by Treatment
        • 11.1.7.2.3 Canada Stomach Cancer Market, by Route of Administration
        • 11.1.7.2.4 Canada Stomach Cancer Market, by Distribution Channel
      • 11.1.7.3 Mexico Stomach Cancer Market
        • 11.1.7.3.1 Mexico Stomach Cancer Market, by Type
        • 11.1.7.3.2 Mexico Stomach Cancer Market, by Treatment
        • 11.1.7.3.3 Mexico Stomach Cancer Market, by Route of Administration
        • 11.1.7.3.4 Mexico Stomach Cancer Market, by Distribution Channel
  • 11.2 Europe
    • 11.2.1 Germany
    • 11.2.2 France
    • 11.2.3 Italy
    • 11.2.4 Spain
    • 11.2.5 United Kingdom
    • 11.2.6 Rest of Europe
  • 11.3 Asia-Pacific
    • 11.3.1 Australia
    • 11.3.2 China
    • 11.3.3 India
    • 11.3.4 Japan
    • 11.3.5 South Korea
    • 11.3.6 Rest of Asia-Pacific
  • 11.4 Middle East and Africa
    • 11.4.1 South Africa
    • 11.4.2 Saudi Arabia
    • 11.4.3 U.A.E
    • 11.4.4 Rest of Middle East and Africa
  • 11.5 South and Central America
    • 11.5.1 Brazil
    • 11.5.2 Argentina
    • 11.5.3 Rest of South and Central America

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Stomach Cancer Market - Key Company Profiles

  • 14.1 Bristol Myers Squibb Company
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Novartis AG
  • 14.3 Merck and Co., Inc.
  • 14.4 Eli Lilly and Company
  • 14.5 Biocon
  • 14.6 Teva Pharmaceutical Industries Ltd.
  • 14.7 Celltrion Healthcare Co., Ltd.
  • 14.8 Samsung Bioepis
  • 14.9 Pfizer Inc.
  • 14.10 Ipsen pharma

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud